Research programme: antidepressants - UCBAlternative Names: UCB-46331
Latest Information Update: 11 Oct 2006
At a glance
- Originator UCB
- Mechanism of Action Histamine H1 receptor antagonists; Serotonin 2 receptor antagonists; Serotonin uptake inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Major depressive disorder
Most Recent Events
- 11 Oct 2006 A lead compound from this programme has entered phase I development
- 30 Mar 2006 Preclinical trials in Depression in Belgium (PO)